May 14th 2021
CPH further derisks acquisition as Halucenex adds to its psychedelics supply
May 6th 2021
Halucenex forms important partnership as psychedelics space heats
April 30th 2021
Revenues up 237%: Creso Pharma delivers strong quarter ahead of OTC listing
April 19th 2021
Move to legalisation of psychedelics could benefit CPH in the US
March 31st 2021
Halucenex agreement to give CPH another leg up in psychedelics
March 23rd 2021
CPH to list on the OTC as it expands North American footprint
March 18th 2021
$15M grant for psychedelics studies as calls to combat mental health intensify
March 15th 2021
Creso Pharma set to be the first ASX listed entrant in new market
Connect with us
